HAVCR2 and acute myeloid leukemia: Earlier, sabatolimab, a monoclonal antibody targeting TIM3, has been developed and underwent phase Ib clinical trial (NCT03066648) in combination with hypomethylating agents, i.e., decitabine and azacitidine, in patients with AML and high-risk myelodysplastic syndromes (MDS) [45].